Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is a promising company due to its innovative and unique approach to drug discovery through the Dynamo platform. The company's pipeline of precision medicines, including RLY-8186, RLY-2608, and RLY-4008, has shown promising efficacy in early clinical trials and targets key limitations of existing therapies. Additionally, their partnership with Pfizer for the supply of atirmociclib for their triplet regimen in front-line metastatic breast cancer provides competitive advantage. However, there are inherent risks in drug development and regulatory approval processes, and the company may need to seek additional equity financing to fund their research, potentially diluting shareholder value.

Bears say

Relay Therapeutics is facing potential risks and challenges such as negative clinical data, slower-than-expected development timelines, and competition in the precision medicine market, which could impact their earlier-stage candidates and ultimately lead to lower-than-projected commercial success and potential dilution risk for investors. Furthermore, their reliance on a DCF-based valuation method may not accurately reflect the company's current and future financial performance.

RLAY has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 9 analysts, RLAY has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.